Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Maralixibat Chloride

FDA-approved product (solution, oral), marketed as Livmarli.

Registered studies
5
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Maralixibat Chloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alagille syndrome
  • Pruritus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for bile therapy
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Maralixibat Chloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Maralixibat Chloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

    NCT05543174 · start 2023-01-16

    Registered record
    Registry ID
    NCT05543174
    Conditions
    Alagille Syndrome (ALGS)
    Interventions
    TAK-625
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-01-16
    Completion
    2025-07-25
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlagille Syndrome (ALGS)
    InterventionTAK-625
    PhasePhase 3
    Registry statusCompleted

  • A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

    NCT05543187 · start 2023-01-10

    Registered record
    Registry ID
    NCT05543187
    Conditions
    Progressive Familial Intrahepatic Cholestasis (PFIC)
    Interventions
    TAK-625
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-01-10
    Completion
    2025-07-22
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Familial Intrahepatic Cholestasis (PFIC)
    InterventionTAK-625
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

    NCT04729751 · start 2021-09-09

    Registered record
    Registry ID
    NCT04729751
    Conditions
    Progressive Familial Intrahepatic Cholestasis; Alagille Syndrome; Cholestatic Liver Disease
    Interventions
    Maralixibat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-09
    Completion
    2024-12-17
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProgressive Familial Intrahepatic Cholestasis; Alagille Syndrome; Cholestatic Liver Disease
    InterventionMaralixibat
    PhasePhase 2
    Registry statusCompleted

  • MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

    NCT04168385 · start 2020-01-16

    Registered record
    Registry ID
    NCT04168385
    Conditions
    Cholestatic Liver Disease
    Interventions
    Maralixibat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-16
    Completion
    2024-09-04
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholestatic Liver Disease
    InterventionMaralixibat
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

    NCT02160782 · start 2014-10-28

    Registered record
    Registry ID
    NCT02160782
    Conditions
    Alagille Syndrome
    Interventions
    LUM001 (Maralixibat); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-10-28
    Completion
    2020-05-28
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlagille Syndrome
    InterventionLUM001 (Maralixibat); Placebo
    PhasePhase 2
    Registry statusCompleted